• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas Product Image

Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas

  • Published: September 2007
  • Region: Global
  • 500 Pages
  • Bioseeker

FEATURED COMPANIES

  • Biogen Idec
  • Cephalon
  • Genentech
  • Genta
  • Immunomedics
  • Protein Design Labs
  • MORE

This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive 500+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.

The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.

The report READ MORE >

1 Executive Summary

2 Methodologies

3 Table of Contents
3.1 List of Tables
3.2 List of Boxes

4 Big Pharma’s R&D Position and Strategy in Oncology: A Summary
4.1 Bristol-Myers Squibb
4.2 GlaxoSmithKline
4.3 Hoffmann-La Roche
4.4 Novartis
4.5 Sanofi-Aventis

5 Last Five Years of Deals and Alliances in Oncology
5.1 Bristol Myers Squibb
5.1.1 Discovery and Lead Molecule Improvements
5.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis
5.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent
5.1.4 The Human Kinome and Cell Cycle Inhibitors
5.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
5.1.6 Erbitux Expansion is Set to Challenge Avastin
5.2 GlaxoSmithKline
5.2.1 The Biopharmaceutical Strategy at GSK
5.2.2 Out Goes Classes of Small Molecule Inhibitors
5.2.3 Marketing and Manufacturing Collaborations
5.2.4 Patient Selectionfo r GSK’s Targeted Cancer Therapies
5.2.5 GSK Taping Into Knowledge Databases
5.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs
5.2.7 Oxford University Helps GSK in India
5.2.8 GSK is Set to Improve Medical Imaging
5.3 Hoffmann-La Roche
5.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery
5.3.2 A New Delivery Route for Avastin?
5.3.3 Improving Antibody Drugs
5.3.4 Roche Strengthens Presence in Genomics Research Market
5.3.5 Target Validation
5.3.6 Drug Discovery Collaborations
5.3.7 Marketing
5.3.8 Outlicensing
5.3.9 Size Doesn’t Matter: Genentech's Goal of Aggressively Pursuing Novel and Innovative Therapies
5.4 Novartis
5.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment
5.4.2 Protein Kinase Inhibitors
5.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors
5.4.4 Novartis Sells of World-Wide Rights
5.4.5 Biomarker and Proteomics Research
5.5 Sanofi-Aventis
5.5.1 Target Screening and Validation
5.5.2 Biologicals
5.5.3 A Short Cut to Success?
5.5.4 Aventis Divests Interest
5.5.5 Recombine My Molecule

6 Competitive R&D Comparison on Oncology Drug Target Level
6.1 Target Overview
6.2 Head to Head Target Comparison by Molecular Function and Cancer Type
6.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.2 Receptor Activity Targets
6.2.3 G-protein Coupled Receptor Activity Targets
6.2.4 Protein Serine/Threonine Kinase Activity Targets
6.2.5 Transcription Factor Activity Targets
6.2.6 Transmembrane Receptor Activity Targets
6.2.7 Catalytic Activity Targets
6.2.8 Cytokine Activity Targets
6.2.9 Protein-Tyrosine Kinase Activity Targets
6.2.10 Kinase Activity Targets
6.2.11 DNA Topoisomerase Activity Targets
6.2.12 Growth Factor Activity Targets
6.2.13 Ligase Activity Targets
6.2.14 Motor Activity Targets
6.2.15 Structural Constituent of Cytoskeleton Targets
6.2.16 Transporter Activity Targets
6.2.17 Targets According to Miscellaneous Molecular Function Groups
6.2.18 Unclassified or Unknown Molecular Function of Targets
6.3 Drug Targets by Target Localization and Compound Type
6.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways
6.4.1 Alpha6 Beta4 Integrin Signaling Pathway
6.4.2 Androgen Receptor Signaling Pathway
6.4.3 B Cell Receptor Signaling Pathway
6.4.4 EGFR1 Signaling Pathway
6.4.5 Hedgehog Signaling Pathway
6.4.6 ID Signaling Pathway
6.4.7 IL-1 Signaling Pathway
6.4.8 IL-2 Signaling Pathway
6.4.9 IL-3 Signaling Pathway
6.4.10 IL-4 Signaling Pathway
6.4.11 IL-5 Signaling Pathway
6.4.12 IL-6 Signaling Pathway
6.4.13 IL-9 Signaling Pathway
6.4.14 Kit Receptor Signaling Pathway
6.4.15 Notch Signaling Pathway
6.4.16 T Cell Receptor Signaling Pathway
6.4.17 TGF-beta Receptor Signaling Pathway
6.4.18 TNF-alpha Signaling Pathway
6.4.19 Wnt Signaling Pathway

7 Drug Compound Type Analysis
7.1 Deployment of Biological Based Compounds by Cancer Indications
7.2 Deployment of Chemical Based Compounds by Cancer Indications
7.3 Deployment of Natural Product Compounds by Cancer Indications

8 Drug Development in Oncology by Major Targeted Therapy Areas
8.1 Angiogenesis
8.2 Antibodies
8.3 Apoptosis
8.4 Protein Kinase Inhibitors
8.5 Vaccines

9 Cancer Indication Focus Analysis
9.1 Preclinical Stage Pipeline
9.2 Phase I Clinical Stage Pipeline
9.3 Phase II Clinical Stage Pipeline
9.4 Phase III Clinical Stage Pipeline
9.5 Drugs Soon to be on the Market
9.6 Approved Drugs

10 Leukemia: An Introduction
10.1 Leukemia Disease Definitions
10.1.1 The Lymphoid Malignancies
10.1.2 The Myeloid Malignancies
10.2 Etiology & Pathophysiology of Leukemia
10.2.1 The Lymphoid Malignancies
10.2.2 The Myeloid Malignancies
10.3 Epidemiology of Leukemia
10.4 Prognosis of Leukemia
10.4.1 The Lymphoid Malignancies
10.4.2 The Myeloid Malignancies

11 Current Treatment Strategies of Leukemia
11.1 The Lymphoid Malignancies
11.2 The Myeloid Malignancies

12 Progress in Current Leukemia Treatment Strategies
12.1 The Lymphoid Malignancies
12.2 The Myeloid Malignancies

13 Key Therapeutic Strategies for Future Leukemia Therapies
13.1 Therapeutic type, Targets & Mechanisms

14 Competitive Landscape in Leukemia Drug Development: The Late Stage Pipeline
14.1 The Lymphoid Malignancies
14.2 The Myeloid Malignancies

15 Current Leukemia Drug Development: The Early Stage Pipeline

16 The Myeloid Malignancies
16.1 The Lymphoid Malignancies

17 Lymphoma: An Introduction
17.1 Disease Definition
17.2 Etiology & Pathophysiology
17.3 Epidemiology

18 Current Lymphoma Treatment Strategies
18.1 Hodgkin's Disease
18.1.1 Radiation Therapy
18.1.2 Chemotherapy
18.1.3 Transplantation
18.1.4 Treatment Option Overview
18.2 Non-Hodgkin's Lymphoma
18.2.1 Radiation Therapy
18.2.2 Chemotherapy
18.2.3 Immunotherapy
18.2.4 Bone Marrow and Peripheral Blood Transplants Watch and Wait
18.2.5 Treatment Option Overview
18.3 Prognosis
18.3.1 Hodgkin's Disease
18.3.2 Non-Hodgkin

19 Progress in Current Lymphoma Treatment Strategies
19.1 HODGKIN
19.2 NON-HODGKIN
19.3 Rituxan
19.4 Bexxar
19.5 Zevalin

20 Key Therapeutic Lymphoma Strategies
20.1 Antibodies & Immunostimulation
20.2 Small molecules: Apoptosis inducers & Kinase inhibitors

21 Competitive Landscape in Lymphoma Drug Development: The Late Stage Pipeline

22 Current Lymphoma Drug Development: The Early Stage Pipeline

23 Appendix I: Antibody Targets by Companies

24 Appendix II: Drugs Approved for the Treatment of Leukemia: A Historical Perspective

25 Appendix III: Selected Companies – Anticancer Pipelines
Accentia BioPharmaceuticals
Biogen Idec
Cell Therapeutics
Cephalon
Chiron Corporation (Now Novartis)
Eli Lilly
Favrille
Genentech
Genitope Corporation
Genmab
Genta
GlaxoSmithKline
Immunomedics
Inex Pharmaceuticals
Millennium Pharmaceuticals
Protein Design Labs
Roche
Sanofi-Aventis
Seattle Genetics
Wyeth

26 Disclaimer

27 Drug Index

28 Company Index

31 List of Tables
Table 1: How to Navigate the Report
Table 2: Number of Pursued Oncology Drugs Targets by Company
Table 3: Pursued Oncology Drugs Targets by Molecular Function
Table 4: Drug Target Expression Profiles in Humans
Table 5: Identified Targets By Cancer Indications
Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets
Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity
Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity
Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets
Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets
Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets
Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets
Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets
Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets
Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets
Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets
Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets
Table 19: Head to Head Comparison of Drugs with Motor Activity Targets
Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets
Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets
Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function
Groups
Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets
Table 24: Drug Target Comparison by Target Localization and Compound Type
Table 25: Targeting Signaling Pathways: An Overview
Table 26: Targeted Signaling Pathway Profiles of Big Pharma
Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway
Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway
Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway
Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway
Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway
Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway
Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway
Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway
Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway
Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway
Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway
Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway
Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway
Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway
Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway
Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway
Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway
Table 44: Deployment of Biological Based Compounds by Cancer Indications
Table 45: Deployment of Chemical Based Compounds by Cancer Indications
Table 46: Deployment of Natural Product Based Compounds by Cancer Indications
Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology
Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage
Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage
Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage
Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage
Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage
Table 53: Summary of Big Pharma’s Preclinical Stage Pipeline
Table 54: Preclinical Stage Pipeline by Cancer Indications
Table 55: Summary of Big Pharma’s Phase I Clinical Stage Pipeline
Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications
Table 57: Summary of Big Pharma’s Phase II Clinical Stage Pipeline
Table 58: Phase II Clinical Stage Pipeline by Cancer Indications
Table 59: Summary of Big Pharma’s Phase III Clinical Stage Pipeline
Table 60: Phase III Clinical Stage Pipeline by Cancer Indications
Table 61: Oncology Drugs Soon to be on the Market
Table 62: Summary of Big Pharma’s Approved Oncology Drugs
Table 63: Approved Drugs by Cancer Indications
Table 105: ALL Classification
Table 106: Latest Approved Drugs for the Treatment of Leukemia
Table 107: Kinase Inhibitors in Development for the Treatment of Leukemia
Table 108: Near Term Progress Rituximab
Table 109: Near Term Progress Oblimersen
Table 110: Near Term Progress Alvocidib
Table 111: Near Term Progress ATRA
Table 112: Near Term Progress GVAX
Table 113: Near Tearm Progress HuM195
Table 114: Near Term Progress Zarnestra
Table 115: Near Term Progress Sorafenib
Table 116: Near Term Progress Valspodar
Table 117: Summary of Current Late Stage Pipeline
Table 118: Near Term Progress CEP-701
Table 119: Near Term Progress PKC412
Table 120: Near Term Progress SU5416
Table 121: Near Term Progress PTK787
Table 122: Near Term Progress VNP40101M
Table 123: Near Term Progress Troxacitabine
Table 124: Near Term Progress Decitabine
Table 125 Near Term Progress Bortezomib
Table 126 Near Term Progress AG-858
Table 127: Near Term Progress bevacizumab
Table 128: Near Term Progress OSI-461
Table 129: Near Term Progress Xcytrin
Table 130: Near Term Progress AP23573
Table 131: Summary of Current Early Stage Pipeline
Table 132 Drugs used in the treatment of lymphoma
Table 133 Summary of Strategies Enhancing Antibody Function
Table 134 Cancer immunotherapy strategies
Table 135 Protein Kinase Targets in Clinical Trials for Lymphoma
Table 136 Recent published studies Aldesleukin
Table 137 Recent published studies Arsenic trioxide
Table 138 Recent published studies BiovaxID
Table 139 Recent published studies Bortezomib
Table 140 Recent published studies epratuzumab
Table 141 Recent published studies FavId
Table 142 Recent published studies MyVax
Table 143 Recent published studies Nelarabine
Table 144 Recent published studies Genasense
Table 145 Recent published studies Pixantrone
Table 146 Recent published studies temsirolimus
Table 147 Recent published studies Zanolimumab
Table 148 Recent published studies Flavopiridol
Table 149 Recent published studies bevacizumab
Table 150 Recent published studies CMC-544
Table 151 Recent published studies galiximab
Table 152 Recent published studies LY317615
Table 153 Recent published studies SGN-40
Table 154 Recent published studies Apolizumab
Table 155 Recent published studies SGN-30
Table 156 Accentia BioPharmaceuticals’ Anticancer Pipeline
Table 157 Biogen-Idec’s Anticancer Pipeline
Table 158 Cell Therapeutics’ Anticancer Pipeline
Table 159 Cephalon’s Anticancer Pipeline
Table 160 Chiron´s Anticancer Pipeline
Table 161 Eli Lilly’s Anticancer Pipeline
Table 162 Favrille anticancer pipeline
Table 163 Genentech’s Anticancer Pipeline
Table 164Genitope’s Anticancer Pipeline
Table 165 Genmab’s Anticancer Pipeline
Table 166 Genta’s Anticancer Pipeline
Table 167 GlaxoSmithKline’s Anticancer Pipeline
Table 168 Immunomedics’ Anticancer Pipeline
Table 169 Inex Pharmaceuticals’ Anticancer Pipeline
Table 170 Millennium Pharmaceuticals’ Anticancer Pipeline
Table 171 Protein Design Labs’ Anticancer Pipeline
Table 172 Roche’s Anticancer Pipeline
Table 173 Sanofi-Aventis anticancer pipeline
Table 174 Seattle Genetics’ Anticancer Pipeline
Table 175 Wyeth’s Anticancer Pipeline

32 List of Boxes
Box 1: Major treatment regimes
Box 2: CLL staging system
Box 3: Updated REAL/WHO Classification for B-Cell Neoplasms
Box 4: Quick Facts - Clofarabine
Box 5: Quick Facts – Alemtuzumab
Box 6: Quick Facts - Gemtuzumab
Box 7: Quick Facts - Imatinib
Box 8: Quick Facts - Rituximab
Box 9: Quick Facts - Genasense
Box 10: Quick Facts - Flavopiridol
Box 11: Quick Facts - Atra
Box 12: Quick Facts - Gvax
Box 13: Quick Facts - Zarnestra
Box 14: Quick Facts – BAY 43-9006
Box 15: Quick Facts - Ceplene
Box 16: Quick Facts - Valspodar
Box 17: Quick Facts - CEP-701
Box 18: Quick Facts - PKC412
Box 19: Quick Facts - SU5416
Box 20: Quick Facts - PTK787
Box 21: Quick Facts - Cloretazine
Box 22: Company statement on progress
Box 23: Quick Facts - Troxacitabine
Box 24: Quick Facts - FK228
Box 25: Quick Facts - Decitabine
Box 26: Quick Facts - VELCADE
Box 27: Velcade sales 2005
Box 28: Quick Facts - AG-858
Box 29: Quick Facts - Avastin
Box 30: Quick Facts - OSI-461
Box 31: Quick Facts - Xcytrin
Box 32: Quick Facts - AP23573
Box 33 Possible Complications of Treatment
Box 34 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 35 Subclassification of Stage
Box 36 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 37 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
Box 38 Staging subclassification system
Box 39 Study details

- Accentia BioPharmaceuticals
- Biogen Idec
- Bristol-Myers Squibb
- Cell Therapeutics
- Cephalon
- Chiron Corporation (Now Novartis)
- Eli Lilly
- Favrille
- Genentech
- Genitope Corporation
- Genmab
- Genta
- GlaxoSmithKline
- Hoffmann-La Roche
- Immunomedics
- Inex Pharmaceuticals
- Millennium Pharmaceuticals
- Novartis
- Protein Design Labs
- Roche
- Sanofi-Aventis
- Seattle Genetics
- Wyeth

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos